Funding & Acknowledgements

Our research is made possible by the support of funding bodies, consortia, institutional partners, and collaborative programs. Their investment enables us to build sensitive analytical platforms for glyco(proteo)mics, develop software that makes analysis scalable, and translate glycosylation biology into biomarker and disease insight.

Institutional Homes & Key Consortia

The research underlying the work of the SUGAR lab was carried out across multiple research environments and collaborations. We gratefully acknowledge:

  • University of Groningen — the current home of the Lageveen-Kammeijer SUGAR Lab within the Groningen Research Institute of Pharmacy (GRIP) and Analytical Biochemistry (AB), Faculty of Science and Engineering.

    • UMCG & FSE infrastructure investment — enabling state-of-the-art MSI capabilities to expand spatial biology and near-future spatial glycomics directions.

  • NWO (VENI) — enabling the development of a single-cell glycomics workflow and oncology-focused glycosylation research.

  • EU / ZonMW (PerMed) — supporting consortium work on biomarker/drug target validation using large-scale biobanking and advanced analytics.

  • Astellas (ISR) — supporting evaluation and extension of PSA glycomics assay development toward clinically relevant applications.

  • Leiden University Medical Center (LUMC) — for the period in which key platform and biomarker assay development was performed, and for the collaborative environment bridging clinical questions with analytical innovation.

  • Cure for Cancer Foundation & Astellas (fellowships) — supporting my PhD trajectory and early postdoctoral development, enabling high-resolution glycosylation workflow development and translation.

  • Health~Holland (TKI-LSH) — supporting translational glycoscience efforts in colorectal cancer (tumor-associated carbohydrate antigens).

  • European consortia & networks (including IBD-BIOM, HighGlycan, GlySign, GlyCoCan) — enabling collaborative science, shared expertise, and doctoral projects across institutions. Supported the work of K. Madunic, V. Kuzyk and A.B. Moran.

  • CSC scholarships — supporting PhD research projects contributing to platform development and application studies of W. Wang, D. Wang and W. Wang.

  • PRINT program — supporting researcher training and innovation within the lab of H.F. Loponte

Specific publications and projects also acknowledge their respective funders and collaborators; we aim to reflect those contributions clearly and consistently.

We sincerely thank our funders, collaborators, and institutional partners for enabling the science—and we aim to honour that support through rigorous, transparent, and openly shared research outputs.

What this support enables

Building a broader research program

Funding and partnerships have supported a cohesive program around high-sensitivity glyco(proteo)mics, from platform development (CE–MS and complementary MALDI strategies) to assay development in oncology and other diseases, and increasingly toward single-cell glycomics and data-driven interpretation.

Examples of funded directions

  • Single-cell glycomics ambition
    Supported by competitive funding that enables us to push detection limits and develop workflows for highly limited material and cellular heterogeneity.

  • Biomarker and translational assays (oncology focus)
    Support has enabled the development and evaluation of protein-of-interest workflows (including PSA-related assay development) and broader biomarker-oriented glyco(proteo)mics studies.

  • Consortium science and data integration
    Collaborative funding supports multi-partner projects that combine biobanking, computational approaches, and robust analytical readouts for biomarker validation and mechanistic insight.

  • Training and talent development
    Fellowships, scholarships, and training programs support PhD candidates, visiting researchers, and early-career development, strengthening both scientific output and community building.